A Mechanistic Study to Assess The Role of Chronotropic Incompetence in Heart Failure With Normal Ejection Fraction (HFNEF)
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2015
Price : $35 *
At a glance
- Drugs Ivabradine (Primary)
- Indications Heart failure
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 08 Dec 2013 Accrual to date is 28% according to United Kingdom Clinical Research Network record.
- 16 Oct 2013 Accrual to date is 25% according to United Kingdom Clinical Research Network record.